(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 255.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 287.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 58.52%.
Soleno Therapeutics's revenue in 2025 is $32,657,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2025 to be $7,783,618,018, with the lowest SLNO revenue forecast at $5,704,053,816, and the highest SLNO revenue forecast at $9,821,197,663.  On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $21,895,212,258, with the lowest SLNO revenue forecast at $13,134,257,524, and the highest SLNO revenue forecast at $30,791,686,765.  
In 2027, SLNO is forecast to generate $36,204,505,931 in revenue, with the lowest revenue forecast at $22,581,845,774 and the highest revenue forecast at $46,460,961,218.